Pubblicazioni

A child with semaphorin 3b-associated membranous nephropathy effectively treated with obinutuzumab after rituximab resistance

2024 - PEDIATRIC NEPHROLOGY

Conversano, E; Debiec, H; Colucci, M; Emma, F; Ronco, P; Vivarelli, M

Single-nucleotide FcÎ³ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma

2021 - BLOOD ADVANCES

Strefford, Jonathan C; Nowicka, Malgorzata; Hargreaves, Chantal E; Burton, Cathy; Davies, Andrew; Ganderton, Rosalind; Hiddemann, Wolfgang; Iriyama, Chisako; Klapper, Wolfram; Latham, Kate V; Martelli, Maurizio; Mir, Farheen; Parker, Helen; Potter, Kathleen N; Rose-Zerilli, Matthew J J; Sehn, Laurie H; TrnÄnÃ½, Marek; Vitolo, Umberto; Bolen, Christopher R; Klein, Christian; Knapp, Andrea; Oestergaard, Mikkel Z; Cragg, Mark S

Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment

2021 - BLOOD ADVANCES

Nowicka, Malgorzata; Hilton, Laura K; Ashton-Key, Margaret; Hargreaves, Chantal E; Lee, Chern; Foxall, Russell; Carter, Matthew J; Beers, Stephen A; Potter, Kathleen N; Bolen, Christopher R; Klein, Christian; Knapp, Andrea; Mir, Farheen; Rose-Zerilli, Matthew; Burton, Cathy; Klapper, Wolfram; Scott, David W; Sehn, Laurie H; Vitolo, Umberto; Martelli, Maurizio; Trneny, Marek; Rushton, Christopher K; Slack, Graham W; Farinha, Pedro; Strefford, Jonathan C; Oestergaard, Mikkel Z; Morin, Ryan D; Cragg, Mark S

CD16 pre-ligation by defucosylated tumor-targeting mAb sensitizes human NK cells to Î³c cytokine stimulation via PI3K/mTOR axis

2020 - CANCER IMMUNOLOGY, IMMUNOTHERAPY

Capuano, Cristina; Pighi, Chiara; Maggio, Roberta; Battella, Simone; Morrone, Stefania; Palmieri, Gabriella; Santoni, Angela; Klein, Christian; Galandrini, Ricciarda

A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: Final analysis of GOYA

2020 - JOURNAL OF HEMATOLOGY & ONCOLOGY

Sehn, L. H.; Martelli, M.; Trneny, M.; Liu, W.; Bolen, C. R.; Knapp, A.; Sahin, D.; Sellam, G.; Vitolo, U.; Sehn, L. H.

Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the Phase 3b GREEN study

2018 - HAEMATOLOGICA

Leblond, V; Aktan, M; Ferra Coll CM, ; Dartigeas, C; Kisro, J; Montillo, M; Raposo, J; Merot, Jl; Robson, S; Gresko, E; Bosch, F; Stilgenbauer, S; FoÃ , R

Obinutuzumab-mediated high-affinity ligation of FcÎ³RIIIA/CD16 primes NK cells for IFNÎ³ production

2017 - ONCOIMMUNOLOGY

Capuano, Cristina; Pighi, Chiara; Molfetta, Rosa; Paolini, Rossella; Battella, Simone; Palmieri, Gabriella; Giannini, Giuseppe; Belardinilli, Francesca; Santoni, Angela; Galandrini, Ricciarda